Allurion Narrows Losses and Advances Toward FDA Submission in Q1 2025; Stock Surges 32%

Stock Information for Allurion Technologies Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Allurion Technologies Inc.

Allurion Announces Initial Results on Combining the Allurion Program With Low-Dose Tirzepatide to Optimize Muscle Mass and GLP-1 Adherence
New Peer-Reviewed Publication Demonstrates Superior Weight Loss and Improved Body Composition with the Allurion Smart Capsule Combined with Lifestyle Intervention Compared to Lifestyle Intervention Alone
Allurion Announces Strategic Distribution Partnership with ProSurg Medical in Brazil to Pioneer New Approach Focused on Metabolically Healthy Weight Loss
Allurion Reports Third Quarter 2025 Financial Results and Provides Business Update
Allurion Passes Critical FDA Milestones, Enters Into Transaction to Exchange All Outstanding Debt That Would Result in the Company Being Debt-Free, and Announces a $5 Million Private Placement Financing
Allurion to Report Third Quarter 2025 Financial Results on November 12, 2025
Allurion Announces Landmark Peer-Reviewed Publication on Consecutive Use of the Allurion Smart Capsule Showing More Than 20% Weight Loss
Allurion to Participate in the ROTH 4th Annual Healthcare Opportunities Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.